File Download
  Patent History
  • Application
    US 12/502548 2009-07-14
  • Publication
    US 2010008925 2010-01-14
Supplementary

published patent: METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES

TitleMETHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES
Priority Date2009-07-14 US 12/502548
2008-07-14 US 12/080558P
Inventors
Issue Date2010
Citation
US Published patent application US 2010008925. Washington, DC: US Patent and Trademark Office (USPTO), 2010 How to Cite?
AbstractBacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 betaA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.
Persistent Identifierhttp://hdl.handle.net/10722/176988

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:54Z-
dc.date.available2012-11-30T08:38:54Z-
dc.date.issued2010-
dc.identifier.citationUS Published patent application US 2010008925. Washington, DC: US Patent and Trademark Office (USPTO), 2010en_HK
dc.identifier.urihttp://hdl.handle.net/10722/176988-
dc.description.abstractBacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 betaA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleMETHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSESen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.hkuros147154-
dc.contributor.inventorLuk, JMCen_HK
dc.contributor.inventorWong Kwong Faien_HK
dc.contributor.inventorPoon, RTPen_HK
dc.contributor.inventorFan, STen_HK
patents.identifier.applicationUS 12/502548en_HK
patents.description.assigneeTHE UNIVERSITY OF HONG KONGen_HK
patents.description.countryUnited States of Americaen_HK
patents.date.publication2010-01-14en_HK
patents.date.application2009-07-14en_HK
patents.date.priority2009-07-14 US 12/502548en_HK
patents.date.priority2008-07-14 US 12/080558Pen_HK
patents.description.ccUSen_HK
patents.identifier.publicationUS 2010008925en_HK
patents.relation.familyCN 102239179 (A) 2011-11-09en_HK
patents.relation.familyUS 2010008925 (A1) 2010-01-14en_HK
patents.relation.familyUS 7960338 (B2) 2011-06-14en_HK
patents.relation.familyWO 2010006508 (A1) 2010-01-21en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats